Management of myoclonus with oral liposomal reduced glutathione
US2010291196A1
Method of treatment of autism spectrum disorder with liposomal reduced glutathione
US2010316700A1
Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury
US2010166846A1
Management of myoclonus with oral liposomal reduced glutathione
US2010233193A1
Systemic administration of nac for vaccination prophylaxis
WO2008036979A2
Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes
WO2007115132A2
Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients
US2009047340A1
Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
WO2007053810A2
Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, preparation, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein
US2009068253A1
Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
EP1868572A2
Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
CA2628777A1
Liposomal formulation for oral administration of glutathione (reduced)
WO0228270A2
The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor
